Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
FTSJ1 CRISPR/Cas9 KO Plasmid (h): sc-411789
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- FTSJ1 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the FTSJ1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: FTSJ1 Antibody (B-2): sc-390355
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
FTSJ1 CRISPR/Cas9 KO Plasmid (h) | sc-411789 | 20 µg | $397.00 |
Overview
FTSJ1 encodes a conserved S-adenosyl-L-methionine–dependent RNA 2′-O-methyltransferase that modifies specific tRNAs to support accurate decoding and efficient translation. By shaping tRNA modification landscapes, FTSJ1 influences proteostasis, stress responses, and global control of protein synthesis that intersects with ribosome function and translational quality control pathways. Disruption of FTSJ1 activity has been linked to neurodevelopmental phenotypes, and pathogenic variants are associated with X-linked intellectual disability, highlighting its importance in neuronal gene expression programs. Altered tRNA modification states connected to FTSJ1 can also impact cell growth and differentiation through downstream effects on translational fidelity.
FTSJ1 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the FTSJ1 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the FTSJ1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the FTSJ1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish FTSJ1 protein expression.
This CRISPR knockout system enables efficient generation of FTSJ1-deficient cell models for investigation of FTSJ1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting FTSJ1 exon(s) critical for FTSJ1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple FTSJ1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by FTSJ1 CRISPR/Cas9 KO Plasmid (h) and FTSJ1 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the FTSJ1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by FTSJ1 HDR Plasmid (h) and FTSJ1 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by FTSJ1 homology arms to support homology-directed repair at defined FTSJ1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.